What are the side effects of Trelegy (fluticasone furoate, umeclidinium, and vilanterol) inhaler?

From the Guidelines

Trelegy inhaler can cause several side effects, including increased risk of pneumonia, which outweighs the risk of pneumonia as an adverse event due to the overall clinical benefit of a reduction in mortality 1. The most common side effects of Trelegy inhaler include:

• Throat irritation
• Hoarseness
• Oral thrush (fungal infection in the mouth)
• Headache
• Upper respiratory tract infections
• Cough Some users may experience more serious side effects such as:
• Worsening of existing infections
• Eye problems like glaucoma or cataracts
• Urinary retention
• Paradoxical bronchospasm (unexpected tightening of airways) Trelegy contains three medications (fluticasone, umeclidinium, and vilanterol) that work together to treat COPD or asthma, but this combination can also increase the risk of cardiovascular effects like increased heart rate or blood pressure in some patients 1. To minimize side effects, patients should:
• Rinse their mouth after each use to prevent thrush
• Use the inhaler exactly as prescribed
• Promptly report any concerning symptoms to their healthcare provider It's essential to balance the therapeutic benefits against potential risks under medical supervision, considering the latest guideline recommendations 1.

From the FDA Drug Label

What are the possible side effects of Fluticasone Furoate/Vilanterol ELLIPTA? Fluticasone Furoate/Vilanterol ELLIPTA can cause serious side effects, including: • fungal infection in your mouth or throat (thrush). • pneumonia • weakened immune system and increased chance of getting infections (immunosuppression). • reduced adrenal function (adrenal insufficiency) • sudden breathing problems immediately after inhaling your medicine. • serious allergic reactions. • effects on heart. • effects on nervous system • bone thinning or weakness (osteoporosis). • slowed growth in children. • eye problems including glaucoma, increased pressure in your eye, cataracts, or other changes in vision. • changes in laboratory blood values, including high levels of blood sugar (hyperglycemia) and low levels of potassium (hypokalemia). Common side effects of Fluticasone Furoate/Vilanterol ELLIPTA include: COPD: • runny nose and sore throat • upper respiratory tract infection • headache • thrush in your mouth or throat. • back pain • pneumonia • bronchitis • inflammation of the sinuses • cough • mouth and throat pain • joint pain • increased blood pressure • flu • fever Asthma: • runny nose and sore throat • thrush in your mouth or throat. • headache • flu • respiratory tract infection • bronchitis • inflammation of the sinuses • mouth and throat pain • hoarseness and voice changes • cough

The side effects of Trelegy inhaler, which contains fluticasone furoate, vilanterol, and umeclidinium, are not directly listed in the provided label, but the label does list the side effects of Fluticasone Furoate/Vilanterol ELLIPTA. Key side effects include:

• Serious side effects: fungal infection, pneumonia, immunosuppression, adrenal insufficiency, sudden breathing problems, serious allergic reactions, effects on heart, effects on nervous system, bone thinning or weakness, slowed growth in children, eye problems, and changes in laboratory blood values.
• Common side effects: runny nose, sore throat, upper respiratory tract infection, headache, thrush, back pain, pneumonia, bronchitis, inflammation of the sinuses, cough, mouth and throat pain, joint pain, increased blood pressure, flu, and fever. 2

From the Research

Side Effects of Trelegy Inhaler

The provided studies do not directly discuss the side effects of the Trelegy inhaler. However, they do provide information on the safety profile of the combination therapy:

• The study 3 mentions that the safety profile of the triple therapy combination was good, without excess cardiovascular effects or pneumonia, although the presence of comorbidities was frequent.
• The study 4 states that findings from phase III/IV trials and real-world setting support the view that fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) may be a useful, safe, and cost-effective option for the maintenance treatment of COPD.

Key Points

• The Trelegy inhaler contains fluticasone furoate, umeclidinium bromide, and vilanterol 5.
• The combination therapy has been shown to be effective in improving lung function, symptoms, and quality of life in patients with COPD 6, 3, 4.
• The safety profile of the combination therapy is generally good, although comorbidities are common 3.
• Real-world studies have demonstrated the effectiveness of FF/UMEC/VI in reducing COPD exacerbations and improving lung function 6, 7.

Comparison with Other Treatments

• A comparative effectiveness study found that FF/UMEC/VI was associated with a lower rate and risk of COPD exacerbations compared to budesonide/glycopyrrolate/formoterol fumarate (BUD/GLY/FORM) 7.
• The study also found that FF/UMEC/VI was associated with a lower risk of all-cause mortality compared to BUD/GLY/FORM 7.